Strs Ohio Buys 11,833 Shares of Iradimed Corp (IRMD)

Strs Ohio raised its holdings in Iradimed Corp (NASDAQ:IRMD) by 263.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,333 shares of the medical equipment provider’s stock after purchasing an additional 11,833 shares during the quarter. Strs Ohio owned 0.15% of Iradimed worth $606,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Northern Trust Corp boosted its position in shares of Iradimed by 119.4% during the second quarter. Northern Trust Corp now owns 58,777 shares of the medical equipment provider’s stock valued at $1,219,000 after buying an additional 31,986 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Iradimed by 46.4% during the second quarter. Bank of New York Mellon Corp now owns 22,588 shares of the medical equipment provider’s stock valued at $469,000 after buying an additional 7,156 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Iradimed by 3,722.5% during the second quarter. Bank of America Corp DE now owns 14,793 shares of the medical equipment provider’s stock valued at $307,000 after buying an additional 14,406 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Iradimed by 119.2% during the second quarter. Renaissance Technologies LLC now owns 117,200 shares of the medical equipment provider’s stock valued at $2,432,000 after buying an additional 63,742 shares during the last quarter. Finally, BlackRock Inc. boosted its position in shares of Iradimed by 427.3% during the second quarter. BlackRock Inc. now owns 229,353 shares of the medical equipment provider’s stock valued at $4,759,000 after buying an additional 185,860 shares during the last quarter. 19.79% of the stock is currently owned by institutional investors.

Several equities research analysts recently commented on the company. BidaskClub raised Iradimed from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 9th. ValuEngine cut Iradimed from a “strong-buy” rating to a “buy” rating in a research report on Saturday. TheStreet raised Iradimed from a “c+” rating to a “b-” rating in a research report on Monday, August 27th. Roth Capital increased their price objective on Iradimed from $21.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, August 1st. Finally, Zacks Investment Research raised Iradimed from a “hold” rating to a “strong-buy” rating and set a $30.00 price objective on the stock in a research report on Tuesday. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Iradimed has an average rating of “Buy” and an average target price of $28.00.

Shares of NASDAQ:IRMD opened at $24.57 on Friday. The stock has a market capitalization of $294.34 million, a price-to-earnings ratio of 307.13 and a beta of 1.90. Iradimed Corp has a 52-week low of $12.51 and a 52-week high of $38.78.

Iradimed (NASDAQ:IRMD) last announced its earnings results on Tuesday, October 30th. The medical equipment provider reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.04. The business had revenue of $7.62 million for the quarter, compared to analysts’ expectations of $7.43 million. Iradimed had a return on equity of 12.20% and a net margin of 16.59%. As a group, equities analysts anticipate that Iradimed Corp will post 0.39 EPS for the current fiscal year.

In other Iradimed news, VP Francis X. Casey sold 55,000 shares of the firm’s stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $29.30, for a total value of $1,611,500.00. Following the transaction, the vice president now directly owns 98,779 shares of the company’s stock, valued at $2,894,224.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 61.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Strs Ohio Buys 11,833 Shares of Iradimed Corp (IRMD)” was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.thelincolnianonline.com/2018/11/10/strs-ohio-buys-11833-shares-of-iradimed-corp-irmd.html.

About Iradimed

IRadimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name.

Read More: What Is An Exchange-Traded Fund (ETF)?

Institutional Ownership by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply